血管紧张素受体阻断剂及低分子量肝素合用对糖尿病肾病治疗作用及研究被引量：1

导出

摘要目的探索血管紧张素受体阻断剂联合低分子量肝素治疗糖尿病肾病的临床疗效。方法将收集到的120例糖尿病肾病患者随机分为观察组和对照组两组,对照组单纯使用替米沙坦进行治疗,观察组在对照组基础上加用低分子量肝素,治疗同时控制患者血糖,给予患者糖尿病饮食,并辅助以适量运动,两组患者均以治疗12周/疗程。结果观察组在UAER含量、肌酐含量的下降明显,较对照组下降更为明显,差异有统计学意义(P<0.05);在治疗效果方面,观察组在显效率和总有效率方面均显著高于对照组且差异显著,差异有统计学意义(P<0.05)。结论血管紧张素受体抑制剂联合低分子量肝素治疗糖尿病肾病效果显著,值得临床上推广使用。

作者刘敏燕

机构地区四川省革命伤残军人医院

出处《中外医疗》 2013年第6期126-126,128,共2页 China & Foreign Medical Treatment

关键词血管紧张素受体拮抗剂低分子量肝素糖尿病肾病疗效观察

分类号 R587.2 [医药卫生—内分泌] R692.9 [医药卫生—泌尿科学]

引文网络
相关文献

参考文献5

1彭仙珍,徐标,肖政.厄贝沙坦联合低分子肝素钠治疗2型糖尿病肾病的疗效及安全性[J].临床荟萃,2009,24(15):1355-1357. 被引量：6
2Sasso F C, Carbonara 0,Persico M, et al. Irbes art an reduces the albu-min excretion rate in microalbuminuric: type-2 diabetie patients in de-pendentiy of hypertension: a randomized double blind placebo -(con-trolled cross over study [J] . Diabetes Care, 2002,25(8):1909-1913.
3Leidig M, Bamhauer R, Kirchertz E J, et al. Efficacy, safety and toiera-bility of valsarl an 80 mg compared to irbesart an 150 mg in hyperten-sive patients on long-term hemodialysis (VALID study)[J]. Clin Nephrol,2008, 69(6):425-432.
4霍丽,彭永德.血管紧张素受体阻断剂用于糖尿病治疗的作用研究[J].世界临床药物,2007,28(11):655-658. 被引量：2
5Rajeswari A, Varalakshmi P. Low molecular weight heparin protection against oxalat e-induced oxidative renal in suit [J] .Clin Chim Acta, 2006, 370(1/2):108-114.

二级参考文献11

1龚辉,张象贤,王亚芬.缬沙坦对高血压病的疗效及其对肱动脉内皮功能的影响[J].中国新药与临床杂志,2004,23(10):661-663. 被引量：12
2许红,胡日红.低分子肝素与普通肝素对血透患者血脂的影响[J].浙江中西医结合杂志,2007,17(1):20-21. 被引量：4
3Rossing K, Schjoedt KJ, Jensen BR, et al. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria[J]. Kidney Int,2005,68(6):1190-1198.
4Sasso FC,Carbonara O,Persico M,et al. Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetie patients independently of hypertension: a randomized doubleblind placebo-controlled crossover study [J]. Diabetes Care, 2002,25(8):1909-1913.
5Cetinkalp SS, Karadeniz MM, Erdogan MA, et al. Short-term effects ofirbesartan treatment on microalbuminuria in patients with normotensive type 2 diabetes[J]. Saudi Med J, 2008,29 (10):1414-1418.
6Leidig M,Bambauer R,Kirchertz EJ ,et al. Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study)[J]. Clin Nephrol,2008,69(6) :425-432.
7Ofili EO, Cable G, Neutel J M, at al. Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in hypertensive women:the inclusive trial[J]. J Womens Health (Larchmt), 2008,17(6) :931-938.
8Deepa PR, Varalakshmi P. The cytoprotective role of a low-molecular-weight heparin fragment studied in an experimental model of glomerulotoxicity[J]. Eur J Pharmacol, 2003,478(2/ 3):199-205.
9Rajeswari A, Varalakshmi P. Low molecular weight heparin protection against oxalate-induced oxidative renal insult [J]. Clin Chim Acta,2006,370(1/2):108-114.
10Nasstrom B,Stegmayr B,Gupta J ,et al. A single bolus of a low molecular weight heparin to patients on haemodialysis depletes lipoprotein lipase stores and retards triglyceride clearing [J]. Nephrol Dial Transplant, 2005,20 (5) : 1172.